Source: ERJ Open Res, 5 (1) 00016-2019; 10.1183/23120541.00016-2019
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Karlijn Hummelink, Mirte Muller, Theodora C. Linders, Vincent van der Noort, Petra M. Nederlof, Paul Baas, Sjaak Burgers, Egbert F. Smit, Gerrit A. Meijer, Michel M. van den Heuvel, Daan van den Broek, Kim Monkhorst. Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ Open Res, 5 (1) 00016-2019; 10.1183/23120541.00016-2019

Member's Comments

No comment yet.

Related content which might interest you: The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity Source: Eur Respir J 2006; 27: 230-232 Year: 2006 Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005 Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 The effect of smoking on phosphoinositide 3-kinase (PI3K) and phosphatase and tensin homolog deleted from chromosome 10 (PTEN) mRNA expression in human airway epithelial cells Source: International Congress 2014 – Mechanistic studies of the airway epithelium Year: 2014 A patient with a lazarus effect on tyrosine kinase inhibition Source: Virtual Congress 2020 – Lung cancer grand round Year: 2020 mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 The proteasome inhibitor bortezomib is effective against experimental malignant pleural effusion Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis Source: ERS Lung Science Conference 2020 Year: 2020 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017